Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly

Exclusion Criteria

• •The patient has received long acting somatostatin analogues within 6 months of study entry
• •The patient has undergone radiotherapy at any time prior to study entry
• •The time between pituitary surgery (if any) and study entry is less than 6 weeks
• •The patient suffers from macroadenoma with visual field defects due to chiasmatic compression